P-709. Incidence of Hospitalizations for Laboratory-Confirmed RSV, COVID-19, and Influenza among Children under-18 years — Respiratory Virus Hospitalization Surveillance Network (RESP-NET), United States, 2022–2024

Abstract Background Respiratory syncytial virus (RSV), SARS-CoV-2, and influenza virus infections are leading causes of severe illness in children. We compared population-based pediatric hospitalization rates for illness associated with these viruses using the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). Methods Children < 18 years hospitalized with RSV, COVID-19, and influenza during October 2022–September 2024 were identified in RESP-NET, which includes patients with positive screening or clinician-directed laboratory test for each virus ≤14 days prior to or during hospitalization at >300 U.S. hospitals. We calculated hospitalization rates by age group and surveillance period, and incidence rate ratios. Results During 2022–2024, 15,843/17,353 (91%) hospitalizations with RSV, 4137/6041 (68%) with COVID-19, and 2822/5863 (48%) with influenza occurred in < 5 year-olds (Table); this age group had the highest hospitalization rates (Figure). Among 0–5 month-olds, RSV hospitalization rates during 2022–2023 and 2023–2024 were 18.0 (15.3–21.5) and 12.4 (10.5–14.9) times higher than respective influenza rates; COVID-19 rates were 4.3 (3.4–5.1) and 3.4 (2.8–4.2) times higher. Among 6–59 month-olds, RSV hospitalization rates were 5.4 (5.0–5.9) and 4.3 (3.9–4.7) times higher; COVID-19 rates did not differ statistically from influenza rates. Among 5–11 year-olds, RSV hospitalization rates were 0.5 (0.4–0.6) times influenza rates in 2023–2024, but not statistically different in 2022–2023; COVID-19 hospitalization rates were 0.4 (0.4–0.5) and 0.3 (0.2–0.3) times influenza rates in 2022–2023 and 2023–2024 respectively. Among 12–17 year-olds, RSV hospitalization rates were 0.3 (0.2–0.4) and 0.3 (0.3–0.4) times influenza rates during 2022-2023 and 2022–2024; COVID-19 rates were 1.3 (1.1–1.5) times influenza rates in 2022-2023 but not statistically different in 2022–2024. Conclusion RSV accounted for the highest hospitalization rates among infants and young children. Among children 5–17 years, hospitalization rates were lower than among those < 5 years and differences in rates between viruses were less pronounced. These findings can help identify age groups at highest risk of hospitalization for each virus and can help guide prevention and treatment strategies. Disclosures Melissa Sutton, MD, MPH, Centers for Disease Control and Prevention Emerging Infections Program: Grant/Research Support

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.921
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-709. Incidence of Hospitalizations for Laboratory-Confirmed RSV, COVID-19, and Influenza among Children under-18 years — Respiratory Virus Hospitalization Surveillance Network (RESP-NET), United States, 2022–2024

Kimberly Yousey‐Hindes, Mila Shakya, Melissa Sutton, Fiona P. Havers et al.
Open Forum Infectious Diseases
Respiratory viral infections research
article

P-709. Incidence of Hospitalizations for Laboratory-Confirmed RSV, COVID-19, and Influenza among Children under-18 years — Respiratory Virus Hospitalization Surveillance Network (RESP-NET), United States, 2022–2024

Kimberly Yousey‐Hindes, Mila Shakya, Melissa Sutton, Fiona P. Havers, Dawud Ujamaa, Alissa O’Halloran, Caroline McCahon, Sarah Rojewski, Catherine Bozio, Monica E P Patton, Erin Licherdell, Pam Daily Kirley, Kyle P P Openo, Grant Barney, Erica Mumm, Ian D Plumb, Holly B Staten, Isaac Armistead
article en

Abstract

Abstract Background Respiratory syncytial virus (RSV), SARS-CoV-2, and influenza virus infections are leading causes of severe illness in children. We compared population-based pediatric hospitalization rates for illness associated with these viruses using the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). Methods Children < 18 years hospitalized with RSV, COVID-19, and influenza during October 2022–September 2024 were identified in RESP-NET, which includes patients with positive screening or clinician-directed laboratory test for each virus ≤14 days prior to or during hospitalization at >300 U.S. hospitals. We calculated hospitalization rates by age group and surveillance period, and incidence rate ratios. Results During 2022–2024, 15,843/17,353 (91%) hospitalizations with RSV, 4137/6041 (68%) with COVID-19, and 2822/5863 (48%) with influenza occurred in < 5 year-olds (Table); this age group had the highest hospitalization rates (Figure). Among 0–5 month-olds, RSV hospitalization rates during 2022–2023 and 2023–2024 were 18.0 (15.3–21.5) and 12.4 (10.5–14.9) times higher than respective influenza rates; COVID-19 rates were 4.3 (3.4–5.1) and 3.4 (2.8–4.2) times higher. Among 6–59 month-olds, RSV hospitalization rates were 5.4 (5.0–5.9) and 4.3 (3.9–4.7) times higher; COVID-19 rates did not differ statistically from influenza rates. Among 5–11 year-olds, RSV hospitalization rates were 0.5 (0.4–0.6) times influenza rates in 2023–2024, but not statistically different in 2022–2023; COVID-19 hospitalization rates were 0.4 (0.4–0.5) and 0.3 (0.2–0.3) times influenza rates in 2022–2023 and 2023–2024 respectively. Among 12–17 year-olds, RSV hospitalization rates were 0.3 (0.2–0.4) and 0.3 (0.3–0.4) times influenza rates during 2022-2023 and 2022–2024; COVID-19 rates were 1.3 (1.1–1.5) times influenza rates in 2022-2023 but not statistically different in 2022–2024. Conclusion RSV accounted for the highest hospitalization rates among infants and young children. Among children 5–17 years, hospitalization rates were lower than among those < 5 years and differences in rates between viruses were less pronounced. These findings can help identify age groups at highest risk of hospitalization for each virus and can help guide prevention and treatment strategies. Disclosures Melissa Sutton, MD, MPH, Centers for Disease Control and Prevention Emerging Infections Program: Grant/Research Support

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Centers for Disease Control and Prevention (US), New Mexico Department of Health (US), New York State Department of Health (US), Michigan Department of Health and Human Services (US), Colorado Department of Public Health and Environment (US), Oregon Health Authority (US), Emory University (US), Lake County (US), University of Rochester Medical Center (US), Yale New Haven Health System (US), Waterborne Environmental (United States) (US), Minnesota Department of Health (US), CDC Foundation (US)
Good health and well-being
Openalex Percentile: Top 92%
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.